IN8bio cuts staff and pipeline to focus on AML cell therapy [Yahoo! Finance]
IN8bio, Inc. (INAB)
Company Research
Source: Yahoo! Finance
As part of the strategic restructuring, the US-based company will reduce its headcount by about 49% and suspend enrolment in the glioblastoma development programme. IN8bio plans to adopt a wait-and-monitor approach for the two studies, the Phase II trial of INB-400 (NCT05664243) and the Phase I trial (NCT04165941) of INB-200, in glioblastoma indications. The company added that it plans to “explore partnership opportunities” for INB-400, an autologous gamma-delta T cell therapy. In addition to job cuts, IN8bio's board and management team will also reduce its cash compensation by 11%, per an SEC filing. The workforce reduction is expected to cost the company $0.3m, mostly in cash severance payments. The news comes a month after IN8bio announced that it had received guidance on the registrational pathway for INB-100 from the US Food and Drug Administration (FDA). To that end, the company plans to add a control cohort to its ongoing Phase I trial (NCT03533816). The prospective cont
Show less
Read more
Impact Snapshot
Event Time:
INAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INAB alerts
High impacting IN8bio, Inc. news events
Weekly update
A roundup of the hottest topics
INAB
News
- IN8bio, Inc. (NASDAQ: INAB) had its price target lowered by analysts at HC Wainwright from $12.50 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire
- IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual MeetingGlobeNewswire
- IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual MeetingGlobeNewswire
INAB
Earnings
- 11/12/24 - Miss
INAB
Sec Filings
- 11/13/24 - Form EFFECT
- 11/12/24 - Form 424B3
- 11/12/24 - Form 10-Q
- INAB's page on the SEC website